David Tanzer

Company: OcuTerra Therapeutics

Job title: Chief Medical Officer

Seminars:

Purpose Engineering Molecules to Adapt Properties for Reaching the Retina 4:30 pm

Exploring the challenges in blood retina barrier permeability Purpose engineering existing molecules to achieve desired properties to reach the retina Investigating preclinical and clinical data to validate successful target deliveryRead more

day: Day One

Panel Discussion: Clinical Trial Safety: How Can Novel Delivery Therapies Match the Intravitreal Standard of Care? 1:15 pm

Evaluating acceptable safety goals for novel therapeutic deliveries Safety challenges associated with incorporating novel delivery technologies: lessons learned from early clinical trials Managing adverse events related to delivery technologies, how do they differ from intravitreal injection therapies?Read more

day: Day One